Financial Performance - IN8bio reported a net loss of $6.2 million, or $0.08 per share, for Q4 2024, compared to a net loss of $7.6 million, or $0.22 per share, in Q4 2023[18]. - Net loss for the year ended December 31, 2024, was $30,437 million, compared to a net loss of $30,007 million in 2023, reflecting a 1.4% increase in losses[24]. - Net loss per share improved to $(0.57) in 2024 from $(1.00) in 2023, showing a significant reduction in loss per share[24]. Cash Position and Funding - The company maintained a cash position of $11.1 million as of December 31, 2024, down from $21.3 million as of December 31, 2023[18]. - The company raised approximately $16.6 million in gross proceeds through equity offerings from 2024 to February 2025, extending its cash runway into March 2026[11]. - The total assets of IN8bio decreased to $20.9 million as of December 31, 2024, from $33.7 million as of December 31, 2023[22]. - The company reported a significant increase in additional paid-in capital to $136.1 million as of December 31, 2024, compared to $116.2 million in the prior year[22]. Research and Development - R&D expenses for Q4 2024 were $3.6 million, a decrease from $4.5 million in Q4 2023, while total R&D expenses for the year were $17.0 million, slightly up from $16.8 million in the prior year[14]. - Research and development expenses were $16,962 million in 2024, slightly up from $16,827 million in 2023, indicating a focus on innovation[24]. - IN8bio's INB-100 program demonstrated a 100% long-term durable response rate in treated Acute Myeloid Leukemia (AML) patients as of January 17, 2025[3]. - IN8bio introduced the INB-600 platform and INB-619, a novel preclinical gamma-delta T cell engager targeting CD19 for oncology and autoimmune diseases[4]. - The company paused enrollment in the Phase 2 INB-400 glioblastoma program to focus resources on other high-impact programs[11]. - IN8bio plans to present updated clinical data in the second half of 2025 and anticipates a potential IND submission for a registrational Phase 2 trial in 2026[14]. Operating Expenses - Total operating expenses for the year ended December 31, 2024, were $30,667 million, an increase from $30,337 million in 2023, representing a 1.1% increase[24]. - The weighted-average number of shares used in computing net loss per share increased to 53,547,030 in 2024 from 29,864,932 in 2023, indicating potential dilution[24].

Ongoing Phase 1 and Phase 2 clinical programs continue to exhibit long-term durable remissions in hard-to-treat cancers, including glioblastoma (GBM) and 100% of treated Acute Myeloid Leukemia (AML) patients remaining relapse-freeExpanded pipeline with INB-600 platform, featuring novel gamma-delta T Cell engager (TCE) targeting CD19 for potential use in oncology and autoimmune diseasesContinued operational execution with strengthened strategic focus on aligning resources in an effort to drive high-impact p ...

Proprietary platform represents the first known approach capable of sustained γδ T cell expansion, eliminating target cells with robust potencyINB-619, a next generation γδ TCE targeting CD19, eradicates B cells in preclinical models, maintaining depletion over time as γδ T cells expand in response to TCE stimulation γδ TCE targets and expands both Vδ1+ and Vδ2+ T cells, potentially leading to longer lasting immune responses and deeper B cell depletionUnlike traditional TCEs and CAR-T therapies, γδ T cells ...

NEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today announced that William Ho, CEO and co-founder, will be presenting at the TD Cowen 45th Annual Health Care Conference on Monday, March 3, 2025, at 10:30 a.m. ET. A live webcast and replay will be available under "Events and Presentations" in the News & Presentations section of the IN8bio website at https://investors.in8bio.com. A ...

NEW YORK, Feb. 24, 2025 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today announced that William Ho, CEO and co-founder, will be presenting at the: H.C. Wainwright 3rd Annual Cell Therapy Virtual ConferenceDate/Time Tuesday, February 25, 2025, at 11:00 a.m. ET. Webcast Link https://journey.ct.events/view/acb6057e-9d9b-427e-b490-eaf85a5c2910 A live webcast and replay will be available under "Events and ...

NEW YORK, Feb. 14, 2025 (GLOBE NEWSWIRE) -- February 14, 2025 – IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, yesterday presented Phase 1 data on its allogeneic gamma-delta T cell therapy, INB-100, at the 2025 Transplantation & Cellular Therapy (TCT) Meetings in Hawaii. The data, previously announced, reinforce INB-100’s potential to significantly reduce post-transplant relapse in high-risk acute myeloid leukemia (AML) patients, p ...

IN8bio (INAB) Update / Briefing February 11, 2025 04:08 PM ET Company Participants Glenn Schulman - Vice President, Head of Investor Relations & Corporate CommunicationsWilliam Ho - Director, President, CEO, and Co-FounderLou Vaickus - Interim CMOMichael R. Bishop - Director of the David and Etta Jonas Center for Cellular Therapy Conference Call Participants None - AnalystRamakanth Swayampakula - Managing Director & Senior Research AnalystSoumit Roy - Biotech Research Analyst Operator Good day, ladies and g ...

Core Insights - IN8bio, Inc. announced promising clinical data for INB-100, an allogeneic gamma-delta T cell therapy for complex leukemias, particularly AML, showing potential for durable long-term remissions and improved survival [1][3][4] Clinical Trial Results - INB-100 demonstrated a 100% complete remission (CR) rate in AML patients across both original and expansion cohorts, with a median follow-up of 20.1 months [4][5] - The original cohort of AML patients achieved a median CR duration of 23.3 months, with some patients remaining in remission for over three years [5] - One-year progression-free survival (PFS) and overall survival (OS) rates for all patients treated with INB-100 were 90.9% and 100%, respectively, while AML patients had 100% PFS and OS at one year [5] Comparison with Historical Data - Historical controls showed a PFS of 67.8% and OS of 74.7% at one year from CIBMTR, and a PFS of 57.4% and OS of 66.7% at one year from KUCC, indicating INB-100's superior outcomes [5] Patient Demographics and Tolerability - The trial included older, high-risk patients (median age = 68) who had complex diseases or had failed multiple prior therapies, yet they achieved durable remissions with manageable side effects [5][6] - INB-100 therapy was well-tolerated, with no significant cytokine release syndrome (CRS) or neurotoxicity reported, and manageable graft-versus-host disease (GvHD) [5][6] Future Outlook - The company is committed to expanding the trial network and preparing for a potential registrational trial, aiming to provide broader patient access to INB-100 [6][9]

Core Insights - IN8bio, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative gamma-delta T cell therapies for cancer treatment [3] - The company will participate in the Biotech Showcase 2025, with CEO William Ho presenting on January 14, 2025 [1][2] Company Overview - IN8bio specializes in gamma-delta T cell-based immunotherapies, which can differentiate between healthy and diseased tissues [3] - The lead program, INB-100, targets acute myeloid leukemia (AML) using haplo-matched allogeneic gamma-delta T cells post-hematopoietic stem cell transplant [3] - The company is also investigating autologous DeltEx DRI gamma-delta T cells for glioblastoma in combination with standard care [3] Event Participation - IN8bio will be present at the Biotech Showcase from January 13-15, 2025, and will also be available for meetings during the J.P. Morgan Health Care Conference from January 13-16, 2025 [2] - The panel discussion titled "The Battle Against Cancer: The Armamentarium Keeps Expanding" will take place on January 13, 2025 [2]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-39692 IN8BIO, INC. (Exact name of Registrant as specified in its Charter) Delaware 82-5462585 (State or other jurisdiction ...